Proactive Investors - Run By Investors For Investors

Next Science lists on ASX after raising $35 million to commercialise Xbio technology

The company has a portfolio of medical products in market and final stages of testing.
Next Science lists on ASX after raising $35 million to commercialise Xbio technology
Xbio is a non-toxic technology that can eradicate chronic bacterial-infected biofilms

Next Science Limited (ASX:NXS) listed on the ASX today after raising $35 million in an initial public offering (IPO) last month to commercialise its anti-bacterial proprietary technology.

Founded in 2012, the Sydney-based biotech has developed products to address the problem of bacterial biofilms that can result in chronic infections.

The company has received financial backing from Australian businessman Lang Walker, with Walker Entities remaining Next Science’s largest shareholder after the IPO.

Four products already in market

An initial suit of four products are currently in market and Next Science has a strong development pipeline with multiple applications across medical devices, over-the-counter drugs and prescription pharmaceuticals.

The launch of the company’s acne treatment is expected to begin in Australia during 2019 under a five-year agreement with Advance Skin Technology Pty Ltd.

A further three new applications of the Xbio technology will be launched over the next 12 months as Next Science finalises partnership negotiations with leading specialist distributors.

These include sinus and middle ear washes as well as antimicrobial washout treatments for minimally invasive surgical procedures.

Numerous ongoing patent applications

Next Science’s products were launched following extensive research and development in the US, including in vitro and in vivo testing, multiple clinical trials, four Federal Drug Administration clearances and more than 70,000 patient episodes of care to date.

The company owns 100% of the intellectual property relating to its Xbio technology platform which is currently protected by 15 patents and 47 patent applications.

Having been already awarded specific patents in wound gel, acne cream, oral rinse and post-surgical disinfection, Next Science has patents under review for acne infections, keloid abatement and minimum ciliotoxicity for use in sinuses and the middle ear.


View full NXS profile View Profile

Next Science Limited Timeline

Related Articles

February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Cameron Durrant
March 05 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use